RELB and breast cancer: Taking into account all these data, our analysis suggests that the expression of specific members of the canonical and alternative NF-κB pathway (IKKβ, p50/NFKB1, p65/RELA, NIK, p52, RELB, and IL-6) are associated with a better prognosis in breast cancer patients regardless of their classification (molecular, grade or LN status).